The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2
Open accessAbstract
Background: Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was to determine whether IL (interleukin)-1 blockade with anakinra improved cardiorespiratory fitness in heart failure with preserved ejection fraction. Methods and Results: Thirty-one patients with heart failure with preserved ejection fraction and CRP (C-reactive protein) >2 mg/L were randomized to anakinra (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. We measured peak oxygen consumption (V o 2 ), ventilatory efficiency (V E /V co 2 slope), and high-sensitivity CRP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 4, 12, and 24 weeks. Twenty-eight patients completed ≥2 visits, 18 women (64%), 27 (96%) obese. There were no differences in peak V o 2 or V E /V co 2 slope between groups at baseline. Peak V o 2 was not changed after 12 weeks of anakinra (from 13.6 [11.8–18.0] to 14.2 [11.2–18.5] mL·kg −1 ·min −1 , P =0.89), or placebo (14.9 [11.7–17.2] to 15.0 [13.8–16.9] mL·kg −1 ·min −1 , P =0.40), without significant between-group differences in changes at 12 weeks (−0.4 [95% CI, −2.2 to +1.4], P =0.64). V E /V co 2 slope was also unchanged with anakinra (from 28.3 [27.2–33.0] to 30.5 [26.3–32.8], P =0.97) or placebo (from 31.6 [27.3–36.9] to 31.2 [27.8–33.4], P =0.78), without significant between-group differences in changes at 12 weeks (+1.2 [95% CI, −1.8 to +4.3], P =0.97). Within the anakinra-treated patients, high-sensitivity CRP and NT-proBNP levels were lower at 4 weeks compared with baseline ( P =0.026 and P =0.022 versus placebo [between-group analysis], respectively). Conclusions: Treatment with anakinra for 12 weeks failed to improve peak V o 2 and V E /V co 2 slope in a group of obese heart failure with preserved ejection fraction patients. The favorable trends in high-sensitivity CRP and NT-proBNP with anakinra deserve exploration in future studies. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02173548.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Balady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., Forman, D., Franklin, B., Guazzi, M., Gulati, M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181e52e69 · Cited by 1,964
Self-citationFletcher, G. F., Balady, G. J., Amsterdam, E. A., Chaitman, B., Eckel, R., Fleg, J., Froelicher, V. F., Leon, A. S., Piña, I. L., Rodney, R., et al. (2001) · Circulation · doi:10.1161/hc3901.095960 · Cited by 1,923
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Kitzman, D. W., Brubaker, P. H., Herrington, D. M., Morgan, T. M., Stewart, K. P., Hundley, W. G., Abdelhamed, A., & Haykowsky, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.033 · Cited by 369
Haykowsky, M. J., Brubaker, P. H., Stewart, K. P., Morgan, T. M., Eggebeen, J., & Kitzman, D. W. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.055 · Cited by 358
Cited by
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Self-citationInflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Hanna, A., & Frangogiannis, N. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07071-0 · Cited by 418
Cellular and molecular pathobiology of heart failure with preserved ejection fraction
Mishra, S., & Kass, D. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00480-6 · Cited by 417
Metadata
- Authors
- Van Tassell, B. W., Trankle, C. R., Canada, J. M., Carbone, S., Buckley, L., Kadariya, D., Del Buono, M. G., Billingsley, H., Wohlford, G., Viscusi, M., Oddi-Erdle, C., Abouzaki, N. A., Dixon, D., Biondi-Zoccai, G., Arena, R., & Abbate, A.
- Venue
- Circulation: Heart Failure
- Published
- 2018-08
- Volume
- 11
- Issue
- 8
- Pages
- e005036-e005036
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2898718238
- Cited by
- 213
- References
- 6
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2. https://app.cochat.ai/papers/10.1161/circheartfailure.118.005036
- The paper
- Van Tassell, B. W., Trankle, C. R., Canada, J. M., Carbone, S., Buckley, L., Kadariya, D., Del Buono, M. G., Billingsley, H., Wohlford, G., Viscusi, M., Oddi-Erdle, C., Abouzaki, N. A., Dixon, D., Biondi-Zoccai, G., Arena, R., & Abbate, A. (2018). IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction: Results From DHART2. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.118.005036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.